Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.

DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS.

Ann Pharmacother. 2016 Nov;50(11):909-917. doi: 10.1177/1060028016660325. Epub 2016 Jul 28.

PMID:
27465881
2.

Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan.

Kinoshita S, Wada K, Matsuda S, Kuwahara T, Sunami H, Sato T, Seguchi O, Yanase M, Nakatani T, Takada M.

Intern Med. 2016;55(7):719-24. doi: 10.2169/internalmedicine.55.5756. Epub 2016 Apr 1.

3.

Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.

Takaki J, Ohno Y, Yamada M, Yamaguchi R, Hisaka A, Suzuki H.

Biol Pharm Bull. 2016 May 1;39(5):863-8. doi: 10.1248/bpb.b16-00014. Epub 2016 Mar 4.

4.

Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.

Pavani A, Naushad SM, Kumar RM, Srinath M, Malempati AR, Kutala VK.

Pharmacogenomics. 2016;17(2):121-31. doi: 10.2217/pgs.15.161. Epub 2015 Dec 15.

PMID:
26666467
5.

Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.

You JH.

Pharmacogenomics. 2015;16(10):1089-100. doi: 10.2217/pgs.15.64. Epub 2015 Jul 31.

PMID:
26230572
6.

Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.

Awad M, Czer LS, Soliman C, Mirocha J, Ruzza A, Pinzas J, Rihbany K, Chang D, Moriguchi J, Ramzy D, Esmailian F, Kobashigawa J, Arabia F.

ASAIO J. 2015 Jul-Aug;61(4):391-6. doi: 10.1097/MAT.0000000000000231.

7.

Changes in Warfarin Sensitivity During Decompensated Heart Failure and Chronic Obstructive Pulmonary Disease.

del Campo M, Roberts G.

Ann Pharmacother. 2015 Sep;49(9):962-8. doi: 10.1177/1060028015590438. Epub 2015 Jun 23.

PMID:
26104049
8.

Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.

Bryk A, Wypasek E, Awsiuk M, Maj D, Undas A.

Cardiovasc Drugs Ther. 2015 Jun;29(3):257-64. doi: 10.1007/s10557-015-6591-8.

PMID:
25986145
9.

Clinical Predictors Associated With Warfarin Sensitivity.

Saleh MI.

Am J Ther. 2016 Nov/Dec;23(6):e1690-e1694.

PMID:
25830869
10.

High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.

Kim YE, Woo HI, On YK, Kim JS, Lee SY.

Eur J Clin Nutr. 2015 Jun;69(6):703-6. doi: 10.1038/ejcn.2015.41. Epub 2015 Apr 1.

PMID:
25828628
11.

Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.

Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K.

Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27.

PMID:
25747538
12.

Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin.

Yamamoto H, Habu Y, Yano I, Ozaki J, Kimura Y, Sato E, Shida A, Fukatsu S, Matsubara K.

Biol Pharm Bull. 2014;37(12):1990-3.

13.

A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity.

Chua YA, Abdullah WZ, Yusof Z, Gan SH.

Biomed Res Int. 2014;2014:316310. doi: 10.1155/2014/316310. Epub 2014 Mar 30.

14.

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Vear SI, Ayers GD, Van Driest SL, Sidonio RF, Stein CM, Ho RH.

Br J Haematol. 2014 Jun;165(6):832-5. doi: 10.1111/bjh.12817. Epub 2014 Mar 6.

15.

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.

Hadjipanagi D, Chrysanthou S, Voskarides K, Deltas C.

BMC Res Notes. 2014 Mar 5;7:123. doi: 10.1186/1756-0500-7-123.

16.

Hematology consult: high-sensitivity warfarin genotype.

Schwer C, Lamana S, Dasanu CA.

Conn Med. 2013 Nov-Dec;77(10):581-5.

PMID:
24367840
17.

Integrated amplification microarray system in a lateral flow cell for warfarin genotyping from saliva.

Sebastian T, Cooney CG, Parker J, Qu P, Perov A, Golova JB, Pozza L, Iwasiow RM, Holmberg R.

Clin Chim Acta. 2014 Feb 15;429:198-205. doi: 10.1016/j.cca.2013.12.009. Epub 2013 Dec 17.

PMID:
24360850
18.

High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase.

Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M.

Pharmacogenomics J. 2014 Aug;14(4):343-9. doi: 10.1038/tpj.2013.41. Epub 2013 Dec 10.

PMID:
24322786
19.

Supplemental Content

Loading ...
Support Center